Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB-729 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort A, Group 1 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks. |
| Cohort A, Group 2 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks. |
| Cohort B, Group 1 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks. |
| Cohort B, Group 2 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| AB-729 | DRUG | subcutaneous injection |
| Peg-IFNα-2a | DRUG | subcutaneous injection |
Inclusion Criteria: * Chronic hepatitis B virus infection with documentation at least 6 months prior to screening * Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently for ≥12 months prior to dosing Day 1 * HBV DNA \<LLOQ at Screening * HBsAg between 100 and 5,000...
AB-729 is an investigational RNA therapy being developed for the treatment of chronic hepatitis B infection. It is designed to reduce hepatitis B surface antigen, or HBsAg, in patients with chronic hepatitis B. It is not approved for any indication and remains in clinical development.
AB-729 targets hepatitis B surface antigen, or HBsAg, which is an antigen produced by the hepatitis B virus. By targeting HBsAg, the RNA therapy aims to lower levels of this viral antigen in patients with chronic hepatitis B infection.
AB-729 is being developed by Arbutus Biopharma Corporation, which trades on the Nasdaq under the ticker ABUS. The company is advancing the candidate for chronic hepatitis B infection.
AB-729 is in Phase 2 clinical development for chronic hepatitis B infection. It is an investigational agent and has not been approved by the FDA or any other regulatory authority for commercial use.
AB-729 has been evaluated in a Phase 2 open-label study, NCT04980482, titled an open-label study of AB-729, nucleos(t)ide analogue and pegylated interferon alfa-2a in subjects with chronic hepatitis B infection. The trial enrolled 43 participants across the United States, Australia, Hong Kong, Moldova, South Korea, Taiwan and Ukraine, and is completed.